Avidity Financial Statements From 2010 to 2025

RNA Stock  USD 28.92  0.63  2.23%   
Avidity Biosciences financial statements provide useful quarterly and yearly information to potential Avidity Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Avidity Biosciences financial statements helps investors assess Avidity Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Avidity Biosciences' valuation are summarized below:
Gross Profit
-250.7 M
Market Capitalization
3.5 B
Enterprise Value Revenue
177.3518
Revenue
10.1 M
Earnings Share
(2.94)
We have found one hundred twenty available fundamental signals for Avidity Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Avidity Biosciences prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Avidity Biosciences Total Revenue

6.43 Million

Check Avidity Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avidity Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 6.9 M, Total Revenue of 6.4 M or Research Development of 230.6 M, as well as many indicators such as Price To Sales Ratio of 75.51, Dividend Yield of 1.0E-4 or PTB Ratio of 1.25. Avidity financial statements analysis is a perfect complement when working with Avidity Biosciences Valuation or Volatility modules.
  
Check out the analysis of Avidity Biosciences Correlation against competitors.
For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

Avidity Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets759 M722.8 M242.5 M
Slightly volatile
Other Current Liabilities48.1 M45.8 M17.6 M
Slightly volatile
Total Current Liabilities97.4 M92.8 M28.7 M
Slightly volatile
Other Liabilities1.1 M1.1 M5.8 M
Slightly volatile
Accounts Payable10.6 M10.1 M4.2 M
Slightly volatile
Cash189.2 M212.8 M124.2 M
Slightly volatile
Other Assets0.860.9343.2 K
Slightly volatile
Long Term Debt1.5 M1.6 M4.7 M
Slightly volatile
Other Current Assets17.9 M17.1 M4.5 M
Slightly volatile
Total Liabilities154.3 M147 M68.1 M
Slightly volatile
Intangible Assets896.8 K939.6 K1.1 M
Slightly volatile
Common Stock6.8 K7.2 K222 K
Slightly volatile
Property Plant Equipment18.1 M17.3 M6.3 M
Slightly volatile
Short and Long Term Debt Total8.6 M11.3 M9.3 M
Pretty Stable
Property Plant And Equipment Net20.1 M19.1 M5.9 M
Slightly volatile
Non Current Assets Total20.8 M19.8 M6.3 M
Slightly volatile
Non Currrent Assets Other537.5 K685.4 K278.7 K
Slightly volatile
Cash And Short Term Investments373.5 M684.7 M195 M
Slightly volatile
Common Stock Total Equity3.4 K3.6 K241.3 K
Slightly volatile
Common Stock Shares Outstanding45.2 M84 M33.8 M
Slightly volatile
Long Term Debt Total1.5 M1.6 MM
Slightly volatile
Liabilities And Stockholders Equity390.4 M722.8 M204.7 M
Slightly volatile
Non Current Liabilities Total37.1 M42.4 M42.6 M
Very volatile
Property Plant And Equipment Gross26.4 M25.2 MM
Slightly volatile
Short and Long Term DebtM3.2 M2.8 M
Slightly volatile
Total Current Assets380.6 M703 M199.1 M
Slightly volatile
Non Current Liabilities Other38.5 K40.5 K145 K
Slightly volatile
Short Term Debt17.9 M17.1 M5.9 M
Slightly volatile
Current Deferred Revenue34.3 M32.6 M9.2 M
Slightly volatile
Net Receivables1.3 M1.3 M994.9 K
Slightly volatile
Short Term Investments495.4 M471.8 M112.9 M
Slightly volatile

Avidity Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue6.4 M8.6 M6.3 M
Very volatile
Research Development230.6 M219.6 M67 M
Slightly volatile
Cost Of Revenue1.8 M1.9 M14.9 M
Slightly volatile
Depreciation And Amortization2.5 M2.4 M828 K
Slightly volatile
Selling General Administrative65.4 M62.3 M17.9 M
Slightly volatile
Other Operating Expenses296 M281.9 M81.7 M
Slightly volatile
Total Operating Expenses296 M281.9 M81.7 M
Slightly volatile
Reconciled Depreciation2.3 M2.1 M778.9 K
Slightly volatile
Selling And Marketing Expenses1.7 M1.9 M2.1 M
Slightly volatile

Avidity Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures5.1 M4.9 M1.8 M
Slightly volatile
Change To Account Receivables557.6 K627.3 K683.9 K
Slightly volatile
Total Cash From Financing Activities135.1 M107.9 M85.6 M
Slightly volatile
End Period Cash Flow200.2 M213.2 M107.7 M
Slightly volatile
Sale Purchase Of Stock485.1 K510.6 K4.8 M
Very volatile
Stock Based Compensation46.2 M44 M11.1 M
Slightly volatile
Change In Working Capital73.8 M70.3 M15.5 M
Slightly volatile
Begin Period Cash Flow199.5 M391.7 M108.8 M
Slightly volatile
Depreciation2.5 M2.4 M828 K
Slightly volatile
Change To Netincome32 M30.5 M9.3 M
Slightly volatile
Change To Liabilities8.2 M15.2 M4.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio75.5179.48937
Slightly volatile
Dividend Yield1.0E-41.0E-41.0E-4
Slightly volatile
Days Sales Outstanding52.0548.5258.1286
Slightly volatile
Stock Based Compensation To Revenue3.783.61.149
Slightly volatile
Capex To Depreciation1.821.811.1428
Slightly volatile
EV To Sales55.4958.41934
Slightly volatile
Payables Turnover0.260.273.8102
Slightly volatile
Sales General And Administrative To Revenue3.15.15.1826
Slightly volatile
Research And Ddevelopement To Revenue10.8217.9818.0042
Slightly volatile
Capex To Revenue0.210.40.1991
Slightly volatile
Cash Per Share6.657.344.0636
Slightly volatile
Days Payables Outstanding1.4 K1.4 K495
Slightly volatile
Current Ratio8.836.825.4685
Slightly volatile
Receivables Turnover6.587.796.5156
Slightly volatile
Graham Number14.6819.0611.5319
Slightly volatile
Capex Per Share0.03490.05210.023
Slightly volatile
Revenue Per Share0.120.13090.0821
Slightly volatile
Interest Debt Per Share0.280.160.3879
Slightly volatile
Debt To Assets0.01710.0181.4674
Slightly volatile
Days Of Payables Outstanding1.4 K1.4 K495
Slightly volatile
Ebt Per Ebit1.171.041.0705
Very volatile
Quick Ratio8.856.825.4768
Slightly volatile
Net Income Per E B T1.171.121.0684
Very volatile
Cash Ratio2.512.644.0897
Slightly volatile
Days Of Sales Outstanding52.0548.5258.1286
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.930.9885
Slightly volatile
Fixed Asset Turnover0.630.661.0146
Pretty Stable
Debt Ratio0.01710.0181.4674
Slightly volatile
Price Sales Ratio75.5179.48937
Slightly volatile
Asset Turnover0.0350.01750.0628
Slightly volatile

Avidity Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap471.5 M530.5 M578.4 M
Slightly volatile
Enterprise Value477.3 M537 M585.5 M
Slightly volatile

Avidity Fundamental Market Drivers

Cash And Short Term Investments595.4 M

Avidity Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Avidity Biosciences Financial Statements

Avidity Biosciences stakeholders use historical fundamental indicators, such as Avidity Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Avidity Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Avidity Biosciences' assets and liabilities are reflected in the revenues and expenses on Avidity Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Avidity Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue32.6 M34.3 M
Total Revenue8.6 M6.4 M
Cost Of Revenue1.9 M1.8 M
Stock Based Compensation To Revenue 3.60  3.78 
Sales General And Administrative To Revenue 5.10  3.10 
Research And Ddevelopement To Revenue 17.98  10.82 
Capex To Revenue 0.40  0.21 
Revenue Per Share 0.13  0.12 
Ebit Per Revenue(28.34)(29.76)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:
Check out the analysis of Avidity Biosciences Correlation against competitors.
For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.94)
Revenue Per Share
0.103
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.18)
Return On Equity
(0.28)
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.